Level Four Advisory Services LLC Increases Stake in Novo Nordisk A/S $NVO

Key Points

• Level Four Advisory Services LLC significantly increased its holdings in Novo Nordisk A/S by 66.2% during Q1, acquiring an additional 53,744 shares, valuing their total holdings at approximately $9.37 million.
• Novo Nordisk A/S reported an earnings per share (EPS) of $0.97 for the last quarter, surpassing analysts' expectations and indicating a robust net margin of 35.60%.
• The company announced a semi-annual dividend of $0.4119, with a payout ratio of 22.53%, amidst a fluctuation in stock price with a 1-year high of $139.74 and a current market cap of $244.42 billion.

Level Four Advisory Services LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 66.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 134,903 shares of the company's stock after acquiring an additional 53,744 shares during the period. Level Four Advisory Services LLC's holdings in Novo Nordisk A/S were worth $9,368,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in NVO. Revolve Wealth Partners LLC raised its stake in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after acquiring an additional 200 shares during the last quarter. First Trust Advisors LP raised its stake in shares of Novo Nordisk A/S by 845.7% during the fourth quarter. First Trust Advisors LP now owns 579,653 shares of the company's stock valued at $49,862,000 after acquiring an additional 518,361 shares during the last quarter. Natixis raised its stake in Novo Nordisk A/S by 966.7% during the fourth quarter. Natixis now owns 27,798 shares of the company's stock worth $2,391,000 after buying an additional 25,192 shares during the last quarter. MML Investors Services LLC raised its stake in Novo Nordisk A/S by 1.9% during the fourth quarter. MML Investors Services LLC now owns 274,230 shares of the company's stock worth $23,589,000 after buying an additional 4,983 shares during the last quarter. Finally, Transce3nd LLC bought a new position in Novo Nordisk A/S during the fourth quarter worth $33,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO traded up $1.4410 during midday trading on Friday, hitting $56.8910. The company's stock had a trading volume of 17,869,499 shares, compared to its average volume of 29,651,820. The stock has a fifty day moving average price of $62.57 and a 200 day moving average price of $69.21. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $139.74. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $254.02 billion, a price-to-earnings ratio of 15.63, a P/E/G ratio of 1.98 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Investors of record on Monday, August 18th will be issued a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date is Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is currently 22.53%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on NVO. Hsbc Global Res downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 31st. TD Cowen reduced their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating for the company in a report on Tuesday, August 19th. HSBC cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective for the company. in a report on Thursday, July 31st. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price objective for the company in a report on Wednesday, August 13th. Finally, Barclays restated an "equal weight" rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Three research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $81.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.